Advertisement

Topics

Search Results for "CT P6 Celltrion"

15:07 EDT 24th June 2017 | BioPortfolio

Matching Channels

None

Matching News

Celltrion Healthcare IPO Set To Benefit From Biosimilar Successes

Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare...   

BRIEF-Celltrion signs contract worth 53.25 bln won

* Says it signed a 53.25 billion won contract with Celltrion Healthcare co.,Ltd, to sell antibody drug

Data show equivalence of Celltrion's copycat to reference drug rituximab

South Korean biopharmaceutical firm Celltrion has showcased data supporting the efficacy and safety of…

Celltrion receives EU approval for Rituxan biosimilar

The European Medicines Agency has approved Celltrion's Truxima, a biosimilar for Roche Holding's leukemia treatment Rituxan/M -More- 

Celltrion making progress with biosimilars in China and Japan

South Korean biotechnology company Celltrion has announced advances in its biosimilar rituximab and trastuzumab programmes in China and Japan.

Celltrion's MabThera cleared by EC for autoimmune diseases and cancer

The European Commission has approved Celltrion Healthcare’s rituximab biosimilar – Truxima (CT-P10) – for the same autoimmune disease and cancer indications as the reference product.

Interview: Celltrion's Journey To The Top

In just 15 years since its establishment, Celltrion has transformed from a modest contract manufacturer in South Korea into a...    

Celltrion's rituximab biosimilar could have four names in EU

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s canc...

Matching PubMed Articles

None

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement